Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01957839
Recruitment Status : Completed
First Posted : October 8, 2013
Last Update Posted : October 8, 2013
Sponsor:
Information provided by (Responsible Party):
Osman Aşıcıoğlu, Istanbul Bakirkoy Maternity and Children Diseases Hospital

Brief Summary:
the investigators examined the hypothesis that hyperprolactinemia may alter uterin, endometrial and intraovarian blood flow and may contribute to increased infertility by another way.

Condition or disease Intervention/treatment Phase
Adverse Reaction to Other Drugs and Medicines Drug: cabergoline treatment Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Study Start Date : March 2010
Actual Primary Completion Date : August 2011
Actual Study Completion Date : September 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: pretreatment group
doppler evaluation at pretreatment period
Experimental: posttreatment group
doppler evaluatıon in normoprolactinemia women who given cabergoline treatment
Drug: cabergoline treatment
cabergoline treatment for hyperprolactinemia group




Primary Outcome Measures :
  1. th effect of prolactin vascular flow and resistance [ Time Frame: the effect of prolactin in vascular resistance at 2 weeks after treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women who had blood prolactin level higher than 25ng/dl

Exclusion Criteria:

  • Pregnancy
  • Use of drugs effecting vasculature such as hormonal therapy, oral contraceptives, antihypertensives
  • Diseases like pelvic inflammatory disease and systemic hypertension
  • Women with clinically overt or treated cardiovascular disease
  • Concurrent illness other than hyperprolactinemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01957839


Locations
Layout table for location information
Turkey
Sisli Etfal Teaching Hosital
Sisli, Turkey
Sponsors and Collaborators
Istanbul Bakirkoy Maternity and Children Diseases Hospital
Investigators
Layout table for investigator information
Principal Investigator: Osman Temizkan, M.D. SİSLİ ETFAL TEACHİNG HOSPİTAL

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Osman Aşıcıoğlu, sisli etfal teaching hospital department gynecology and obstetric, Istanbul Bakirkoy Maternity and Children Diseases Hospital
ClinicalTrials.gov Identifier: NCT01957839     History of Changes
Other Study ID Numbers: Aşıcıoğlu-08
OA8 ( Other Identifier: Doppler )
First Posted: October 8, 2013    Key Record Dates
Last Update Posted: October 8, 2013
Last Verified: October 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Cabergoline
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs